Abstract Body

Low CD4/CD8 ratios may increase risk of clinical events, and earlier antiretroviral therapy (ART) may lead to a higher likelihood of CD4/CD8 normalization. We estimated time to CD4/CD8 normalization following ART initiation and risk of mortality and serious clinical events among acutely and chronically infected patients.

Patients who achieved HIV RNA suppression within 1 year of ART initiation between 2000 and 2014, were included from the UNC CFAR HIV Clinical Cohort Study (chronic HIV infection, CHI) and the Acute HIV Infection Study (acute HIV infection, AHI). Normalization was defined as a ratio ≥1. Kaplan-Meier and multivariable Cox proportional hazards methods were used to model time from ART initiation to normalization and outcomes of interest, adjusting for baseline covariates.

AHI patients (n=102) were younger and more likely men than CHI patients (n=545), (median 28 vs. 38 years old; 89% vs. 73%; both p<0.001). At ART initiation AHI versus CHI patients had higher CD4 (median 489 vs. 203 cells/mm3; p<0.001) and were more likely to have a normal CD4/CD8 ratio, 14% and 2%, respectively. 57% and 14% of AHI and CHI patients had normal ratios at 1 year of suppressive ART, respectively. Median times to normalization were 6, 16, 43, 51 and >125 months among AHI and CHI patients with ART initiation CD4>500, 350, 200-350 and <200 cells/mm3, respectively (log-rank p<0.001). In multivariable analyses AHI patients had shorter time to normalization (Hazard Ratio [HR]=2.7, 95% Confidence Interval [CI] 2.0-3.7), as did older patients and those with a higher CD4 (HR=1.14, 1.0-1.3 per 10 years; HR=1.3, 1.3-1.4 per 100 CD4). Among patients initiating ART with CD4>500, AHI patients also had shorter time to normalization with adjusted HR of 1.9 (1.2, 3.1). During 4,097 person-years of follow-up, 92 patients died. Having a normalized CD4/CD8 ratio at 1 year post-ART initiation had no apparent effect on all-cause mortality or a composite endpoint of serious non-AIDS clinical events and mortality (HR=0.8, 0.4-1.8; HR=1.1, 0.6-2.0; respectively).

CD4/CD8 normalization occurred earlier among AHI versus CHI patients but early normalization did not appear to predict mortality and serious non-AIDS events using a stringent criterion for normalization. The effect of longitudinal CD4/CD8 ratios on serious clinical events among patients on suppressive ART is important to evaluate given proposed hypotheses of an association with immune activation and immunosenescence.